Atorvastatin 40 mg/day was not significantly more effective than placebo in the treatment of plaque-type psoriasis in patients with baseline PASI scores less than 12 and receiving standard topical psoriasis therapy. Any therapeutic benefit was attributed to the effects of emollients and the topical therapies applied concomitantly. The lack of significant effect from atorvastatin could be attributed to the patient population, which had relatively low baseline PASI scores. Additional trials are needed to elucidate the place of atorvastatin and other statins for the treatment of psoriasis. We propose a larger follow-up study as well as testing atorvastatin in a more severely affected group characterized by high PASI scores. Further testing with atorvastatin in high doses, rather than standard doses, or in a dose-ranging study is recommended.
Pharmacotherapy. 2011;31(11):1045-1050. © 2011 Pharmacotherapy Publications
Cite this: Atorvastatin for the Treatment of Plaque-type Psoriasis - Medscape - Nov 01, 2011.